Alto Neuroscience, Inc. (ANRO) surged 53.51 percent to $6.77 on Friday after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to its investigational drug ALTO-101 for the treatment of cognitive impairment associated with schizophrenia. Shares opened at $4.76 and traded between $4.72 and $7.15 during the session, compared with a prior close of $4.41 on the New York Stock Exchange. Current bids are at $6.63 with asks at $6.64. Trading volume spiked to 42.47 million shares, far above the average of 100,207. The stock has traded between $1.60 and $15.04 over the past 52 weeks.
The PDE4 inhibitor has shown pro-cognitive effects in healthy volunteers, and a Phase 2 proof-of-concept trial in CIAS patients is ongoing.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.